Skip to main content

5AM Venture Management, LLC

13F filer · CIK 0001799883
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$288MU.S. long equity reported on 13F
Positions160 new · 4 closed
Net flow last quarter-$110MBuys minus sells
Top 10 positions weight85.6%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202616 positions
MPLTMapLight Therapeutics, Inc.$34M11.83%2.09%Not reportedQ4 2025
TYRATyra Biosciences, Inc.$32.9M11.42%1.73%Not reportedQ3 2023
TRDAEntrada Therapeutics, Inc.$29.9M10.37%10.42%Not reportedQ4 2021
PHVSPharvaris N.V.$27.6M9.58%1.22%Not reportedQ2 2022
CAMPCamp4 Therapeutics Corp$25.6M8.91%11.30%Not reportedQ4 2024
ARTVArtiva Biotherapeutics, Inc.$22.8M7.93%9.52%Not reportedQ3 2024
TECXTectonic Therapeutic, Inc.$20.9M7.24%3.15%Not reportedQ2 2024
ZNTLZentalis Pharmaceuticals, Inc.$19.1M6.65%5.51%Not reportedQ2 2023
CLDXCelldex Therapeutics, Inc.$18.5M6.43%0.63%Not reportedQ2 2023
EYPTEyePoint, Inc.$15M5.22%1.24%Not reportedQ2 2024
BHVNBiohaven Ltd.$11M3.82%0.49%Not reportedQ4 2023
SRZNSurrozen, Inc.$7.04M2.44%2.31%-30.0%Q1 2025
SKYESkye Bioscience, Inc.$6.71M2.33%27.55%Not reportedQ2 2024
ALXOAlx Oncology Holdings Inc$6.33M2.20%2.21%Not reportedQ1 2026
TARAProtara Therapeutics, Inc.$5.23M1.82%2.32%Not reportedQ4 2024
SLNSilence Therapeutics plc$5.23M1.82%0.34%Not reportedQ1 2024
Q1 2026Reported May 15, 202620 positions
ERASErasca, Inc.$56.4M15.66%1.12%-35.5%Q2 2024
TRDAEntrada Therapeutics, Inc.$51.2M14.21%10.45%Not reportedQ4 2021
TYRATyra Biosciences, Inc.$39.4M10.94%1.73%Not reportedQ3 2023
CAMPCamp4 Therapeutics Corp$25.9M7.19%11.30%Not reportedQ4 2024
CNTACentessa Pharmaceuticals PLC$23.1M6.41%0.38%Not reportedQ1 2024
PHVSPharvaris N.V.$22.5M6.26%1.22%Not reportedQ2 2022
MPLTMapLight Therapeutics, Inc.$19.3M5.36%2.10%Not reportedQ4 2025
TECXTectonic Therapeutic, Inc.$18.8M5.21%3.22%Not reportedQ2 2024
CLDXCelldex Therapeutics, Inc.$15.8M4.38%0.75%Not reportedQ2 2023
ARTVArtiva Biotherapeutics, Inc.$15.2M4.21%9.52%Not reportedQ3 2024
EYPTEyePoint, Inc.$13.5M3.76%1.26%Not reportedQ2 2024
SRZNSurrozen, Inc.$11.3M3.13%3.37%Not reportedQ1 2025
ZNTLZentalis Pharmaceuticals, Inc.$9.24M2.56%5.55%Not reportedQ2 2023
GHRSGH Research PLC$8.05M2.24%0.92%Not reportedQ2 2023
TARAProtara Therapeutics, Inc.$7.14M1.98%2.49%Not reportedQ4 2024
BHVNBiohaven Ltd.$6.25M1.74%0.49%Not reportedQ4 2023
ALXOAlx Oncology Holdings Inc$6.13M1.70%2.21%NewQ1 2026
SKYESkye Bioscience, Inc.$5.95M1.65%27.56%Not reportedQ2 2024
RLYBRallybio Corp$2.62M0.73%5.52%-35.7%Q3 2021
SLNSilence Therapeutics plc$2.51M0.70%0.34%Not reportedQ1 2024
Q4 2025Reported Feb 17, 202621 positions
TRDAEntrada Therapeutics, Inc.$41.7M13.11%10.60%-4.7%Q4 2021
CAMPCamp4 Therapeutics Corp$36M11.31%11.31%Not reportedQ4 2024
TYRATyra Biosciences, Inc.$27.1M8.51%1.92%+9.6%Q3 2023
VRDNViridian Therapeutics, Inc.\DE$22.9M7.21%0.72%Not reportedQ3 2022
PHVSPharvaris N.V.$22.1M6.96%1.22%Not reportedQ2 2022
ERASErasca, Inc.$20.1M6.32%1.90%Not reportedQ2 2024
EYPTEyePoint, Inc.$19.2M6.03%1.27%Not reportedQ2 2024
MPLTMapLight Therapeutics, Inc.$16.7M5.25%2.16%NewQ4 2025
CNTACentessa Pharmaceuticals PLC$14.5M4.57%0.39%-14.7%Q1 2024
CLDXCelldex Therapeutics, Inc.$13.5M4.25%0.75%Not reportedQ2 2023
TECXTectonic Therapeutic, Inc.$12.7M3.98%3.24%+18.6%Q2 2024
ELVNEnliven Therapeutics, Inc.$11.9M3.74%1.30%Not reportedQ1 2023
ARTVArtiva Biotherapeutics, Inc.$10.1M3.17%9.59%Not reportedQ3 2024
SRZNSurrozen, Inc.$8.76M2.75%3.96%+25.0%Q1 2025
BHVNBiohaven Ltd.$8.34M2.62%0.56%+54.3%Q4 2023
TARAProtara Therapeutics, Inc.$7.3M2.30%2.56%+71.2%Q4 2024
GHRSGH Research PLC$7.27M2.29%0.92%Not reportedQ2 2023
SKYESkye Bioscience, Inc.$7.26M2.28%29.01%Not reportedQ2 2024
ZNTLZentalis Pharmaceuticals, Inc.$5.33M1.68%5.71%+705.7%Q2 2023
SLNSilence Therapeutics plc$2.9M0.91%0.34%Not reportedQ1 2024
RLYBRallybio Corp$2.49M0.78%68.72%Not reportedQ3 2021
Q3 2025Reported Nov 14, 202525 positions
SKYESkye Bioscience, Inc.$38M13.94%31.24%-2.3%Q2 2024
TRDAEntrada Therapeutics, Inc.$24.7M9.04%11.14%-1.2%Q4 2021
PHVSPharvaris N.V.$19.9M7.29%1.47%Not reportedQ2 2022
CAMPCamp4 Therapeutics Corp$17.6M6.45%12.52%+100.5%Q4 2024
CNTACentessa Pharmaceuticals PLC$16.5M6.05%0.51%-18.1%Q1 2024
VRDNViridian Therapeutics, Inc.\DE$15.9M5.82%0.90%Not reportedQ3 2022
ELVNEnliven Therapeutics, Inc.$15.8M5.79%1.30%Not reportedQ1 2023
EYPTEyePoint, Inc.$15M5.48%1.51%Not reportedQ2 2024
DNTHDianthus Therapeutics, Inc.$14.4M5.26%0.85%-62.9%Q3 2023
TYRATyra Biosciences, Inc.$13.1M4.81%1.76%Not reportedQ3 2023
CLDXCelldex Therapeutics, Inc.$12.9M4.71%0.75%Not reportedQ2 2023
ERASErasca, Inc.$11.8M4.32%1.91%Not reportedQ2 2024
PRAXPraxis Precision Medicines, Inc.$9.01M3.30%0.80%Not reportedQ1 2024
GHRSGH Research PLC$8.19M3.00%1.10%Not reportedQ2 2023
TECXTectonic Therapeutic, Inc.$8.03M2.94%2.73%Not reportedQ2 2024
BHVNBiohaven Ltd.$7.19M2.63%0.45%Not reportedQ4 2023
ARTVArtiva Biotherapeutics, Inc.$6.75M2.47%9.63%Not reportedQ3 2024
SRZNSurrozen, Inc.$3.99M1.46%3.62%Not reportedQ1 2025
TARAProtara Therapeutics, Inc.$3.48M1.27%2.07%Not reportedQ4 2024
ALECAlector, Inc.$2.95M1.08%0.93%Not reportedQ4 2024
SLNSilence Therapeutics plc$2.47M0.91%0.34%Not reportedQ1 2024
ADVMAdverum Biotechnologies, Inc.$2.45M0.90%2.58%Not reportedQ1 2024
RLYBRallybio Corp$1.81M0.66%8.66%Not reportedQ3 2021
ZNTLZentalis Pharmaceuticals, Inc.$740K0.27%0.68%Not reportedQ2 2023
MRSNMersana Therapeutics, Inc.$405K0.15%1.04%-96.0%Q1 2023
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.